Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1981 Nov;68(5):1272–1276. doi: 10.1172/JCI110373

Estimated rate of prostacyclin secretion into the circulation of normal man.

G A FitzGerald, A R Brash, P Falardeau, J A Oates
PMCID: PMC370922  PMID: 7028786

Abstract

The rate of secretion of prostacyclin (PGI2) into the circulation of normal man was estimated by measurement of the 2,3-dinor-6-keto-PGF1 alpha (D) and 15-keto-13,14-dihydro-2,3-dinor-6-keto-PGF1 alpha (KDD) urinary metabolites of PGI2. Subjects received 6-h intravenous infusions of vehicle alone and PGI2 at 0.1, 0.4, and 2.0 ng/kg per min in random order. The fractional elimination of the metabolites was independent of the rate of PGI2 infusion. 6.8 +/- 0.3% of the infused PGI2 appeared as D and 4.1 +/- 0.4% as KDD. The regression of infused PGI2 upon the quantities of the two metabolites excreted in excess of control values permitted estimation of the rate of entry of endogenous PGI2 into the circulation corresponding to a given quantity of metabolite excreted. Using the quantities excreted in the 24 h from commencement of the infusions the estimated rates were 0.08 +/- 0.02 ng/kg per min from D and 0.10 +/- 0.03 from KDD. Studies with exogenous PGI2 suggest that infusion rates 2--4 ng/kg per min are required to achieve the threshold for inhibition of platelet function (ex vivo) in man. Although not precluding a role for PGI2 in local platelet-vessel wall interactions, the much lower estimates obtained in this study suggest that endogenous PGI2 is unlikely to act as a circulating antiplatelet agent in healthy man.

Full text

PDF
1272

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong J. M., Lattimer N., Moncada S., Vane J. R. Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol. 1978 Jan;62(1):125–130. doi: 10.1111/j.1476-5381.1978.tb07014.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Claeys M., Van Hove C., Duchateau A., Herman A. G. Quantitative determination of 6-Oxo-PGF1 alpha in biological fluids by gas chromatography mass spectrometry. Biomed Mass Spectrom. 1980 Nov;7(11-12):544–548. doi: 10.1002/bms.1200071119. [DOI] [PubMed] [Google Scholar]
  3. Ferreira S. H., Vane J. R. Prostaglandins: their disappearance from and release into the circulation. Nature. 1967 Dec 2;216(5118):868–873. doi: 10.1038/216868a0. [DOI] [PubMed] [Google Scholar]
  4. FitzGerald G. A., Friedman L. A., Miyamori I., O'Grady J., Lewis P. J. A double blind placebo controlled crossover study of prostacyclin in man. Life Sci. 1979 Aug 20;25(8):665–672. doi: 10.1016/0024-3205(79)90507-1. [DOI] [PubMed] [Google Scholar]
  5. Gorman R. R., Bunting S., Miller O. V. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins. 1977 Mar;13(3):377–388. doi: 10.1016/0090-6980(77)90018-1. [DOI] [PubMed] [Google Scholar]
  6. Gryglewski R. J., Korbut R., Ocetkiewicz A. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature. 1978 Jun 29;273(5665):765–767. doi: 10.1038/273765a0. [DOI] [PubMed] [Google Scholar]
  7. Gryglewski R. J., Korbut R., Ocetkiewicz A., Stachura J. In vivo method for quantitation for anti-platelet potency of drugs. Naunyn Schmiedebergs Arch Pharmacol. 1978 Mar;302(1):25–30. doi: 10.1007/BF00586592. [DOI] [PubMed] [Google Scholar]
  8. Hensby C. N., Barnes P. J., Dollery C. T., Dargie H. Production of 6-oxo-PGF1 alpha by human lung in vivo. Lancet. 1979 Dec 1;2(8153):1162–1163. doi: 10.1016/s0140-6736(79)92388-2. [DOI] [PubMed] [Google Scholar]
  9. Hensby C. N., Fitzgerald G. A., Friedman L. A., Lewis P. J., Dollery C. T. Measurement of 6-oxo-PGF1 alpha in human plasma using gas chromatography-mass spectrometry. Prostaglandins. 1979 Nov;18(5):731–736. doi: 10.1016/0090-6980(79)90093-5. [DOI] [PubMed] [Google Scholar]
  10. Mitchell M. D. A sensitive radioimmunoassay for 6-keto-prostaglandin F1alpha: preliminary observations on circulating concentrations. Prostaglandins Med. 1978 Jul;1(1):13–21. doi: 10.1016/0161-4630(78)90072-1. [DOI] [PubMed] [Google Scholar]
  11. Moncada S., Korbut R., Bunting S., Vane J. R. Prostacyclin is a circulating hormone. Nature. 1978 Jun 29;273(5665):767–768. doi: 10.1038/273767a0. [DOI] [PubMed] [Google Scholar]
  12. Moncada S., Vane J. R. Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull. 1978 May;34(2):129–135. doi: 10.1093/oxfordjournals.bmb.a071482. [DOI] [PubMed] [Google Scholar]
  13. Pace-Asciak C. R., Carrara M. C., Levine L., Nicolaou K. C. PGI2-specific antibodies administered in vivo suggest against a role for endogenous PGI2 as a circulating vasodepressor hormone in the normotensive and spontaneously hypertensive rat. Prostaglandins. 1980 Dec;20(6):1053–1060. doi: 10.1016/0090-6980(80)90059-3. [DOI] [PubMed] [Google Scholar]
  14. Rosenkranz B., Fischer C., Reimann I., Weimer K. E., Beck G., FRölich J. C. Identification of the major metabolite of prostacyclin and 6-ketoprostaglandin F1 alpha in man. Biochim Biophys Acta. 1980 Aug 11;619(2):207–213. doi: 10.1016/0005-2760(80)90069-7. [DOI] [PubMed] [Google Scholar]
  15. Rosenkranz B., Fischer C., Weimer K. E., Frölich J. C. Metabolism of prostacyclin and 6-keto-prostaglandin F1 alpha in man. J Biol Chem. 1980 Nov 10;255(21):10194–10198. [PubMed] [Google Scholar]
  16. Smith J. B., Ogletree M. L., Lefer A. M., Nicolaou J. C. Antibodies which antagonise the effects of prostacyclin. Nature. 1978 Jul 6;274(5666):64–65. doi: 10.1038/274064a0. [DOI] [PubMed] [Google Scholar]
  17. Steer M. L., MacIntyre D. E., Levine L., Salzman E. W. Is prostacyclin a physiologically important circulating anti-platelet agent? Nature. 1980 Jan 10;283(5743):194–195. doi: 10.1038/283194a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES